Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)
A. Guenther (Giessen, Germany), A. Prasse (Hannover, Germany), M. Kreuter (Heidelberg, Germany), P. Neuser (Marburg, Germany), K. Rabe (Grossharnsdorf, Germany), F. Bonella (Essen, Germany), R. Bonnet (Bad Berka, Germany), C. Grohe (Berlin, Germany), M. Held (Würzburg, Germany), H. Wilkens (Homburg, Germany), P. Hammerl (Immenhausen, Germany), D. Koschel (Dresden, Germany), S. Blaas (Regensburg, Germany), H. Wirtz (Leipzig, Germany), J. Ficker (Nürnberg, Germany), W. Neumeister (Koblenz, Germany), N. Schönfeld (Berlin, Germany), M. Claussen (Grossharnsdorf, Germany), N. Kneidinger (Munich, Germany), M. Frankenberger (Munich, Germany), S. Hummler (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), S. Tello (Giessen, Germany), J. Freise (Hannover, Germany), T. Welte (Hannover, Germany), C. Schade-Brittinger (Marburg, Germany), J. Behr (Münich, Germany)
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Guenther (Giessen, Germany), A. Prasse (Hannover, Germany), M. Kreuter (Heidelberg, Germany), P. Neuser (Marburg, Germany), K. Rabe (Grossharnsdorf, Germany), F. Bonella (Essen, Germany), R. Bonnet (Bad Berka, Germany), C. Grohe (Berlin, Germany), M. Held (Würzburg, Germany), H. Wilkens (Homburg, Germany), P. Hammerl (Immenhausen, Germany), D. Koschel (Dresden, Germany), S. Blaas (Regensburg, Germany), H. Wirtz (Leipzig, Germany), J. Ficker (Nürnberg, Germany), W. Neumeister (Koblenz, Germany), N. Schönfeld (Berlin, Germany), M. Claussen (Grossharnsdorf, Germany), N. Kneidinger (Munich, Germany), M. Frankenberger (Munich, Germany), S. Hummler (Heidelberg, Germany), N. Kahn (Heidelberg, Germany), S. Tello (Giessen, Germany), J. Freise (Hannover, Germany), T. Welte (Hannover, Germany), C. Schade-Brittinger (Marburg, Germany), J. Behr (Münich, Germany). Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). 1879
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Exploring Efficacy and Safety of Oral Pirfenidone for Progressive, non-IPF Lung Fibrosis (RELIEF-Study) Source: International Congress 2017 – New ideas for the management of chronic lung diseases Year: 2017
Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021
Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020
Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Late Breaking Abstract - Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Late Breaking Abstract - Lung deflation with Indacaterol/Glycopyrronium improves cardiac function in COPD patients: The CLAIM Study Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - SUPRAnav: A Clinical Trial Evaluating the Efficacy and Safety of a New Invention Device Designed for Continuous Supraglottic Aspiration in Mechanically Ventilated Patients. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019
Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020
Late Breaking Abstract - First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment For Chronic Bronchitis (CB) Source: International Congress 2018 – Interventional pulmonology highlights in 2018: latest innovations Year: 2018
LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014
Late Breaking Abstract - Clinical Efficacy and Safety of Macitentan Transitioned from Bosentan in Patients with Pulmonary Arterial Hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018
Late Breaking Abstract - Does The High Use Of Oral Antiasthmatics Contribute To The Elevated Burden Of Asthma In India? Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Late Breaking Abstract - Bronchial Rheoplasty For Treatment of Chronic Bronchitis: 6 Month Results from a Prospective Multi-Center Study Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): clinical problems Year: 2017
Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT) Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Late Breaking Abstract - Bronchoscopic Thermal Vapor Ablation (BTVA) Outcomes at 12 months in Emphysema Patients with Severe Hyperinflation, a STEP-UP RCT Subgroup Analysis Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
LATE-BREAKING ABSTRACT: TITLE: Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial (RCT) and Economic Evaluation (The SABRE Study) Source: International Congress 2014 – Prevention, diagnosis and consequences of respiratory infections in children Year: 2014
Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019